Human embryonic stem cell-derived mesenchymal stromal cells.
Human embryonic stem cell-derived mesenchymal stromal cells.
复制标题
DOI：
10.1111/j.1537-2995.2011.03376.x
复制
发表时间：
2011-11
期刊：
影响因子：
2.9
通讯作者：
Hematti P
中科院分区：
文献类型：
--
作者：
Hematti P
骨髓间充质干细胞（Mesenchymal stromal cells，MSCs）具有多向分化潜能，具有良好的免疫调节和抗炎作用，在再生细胞治疗中具有广泛的应用前景。具有相似表型特征的细胞现在已经从几乎所有的胎儿、新生儿和成人组织中获得;此外，最近也从人胚胎干细胞（ESC）中产生了相似的细胞。从人胚胎干细胞产生MSC提供了在体外研究人间充质谱系产生的发育生物学的机会。从人ESC衍生的MSC产生骨和软骨及其在体外和体内的功能表征也是一个活跃的研究领域，因为ESC可以提供无限的MSC来源用于骨和软骨缺损的潜在修复。来自成人来源的MSC正在许多I-III期临床试验中用于各种各样的适应症，主要基于其免疫调节特性。我们的研究小组和其他研究人员已经表明，来源于人ESC的MSC具有与骨髓来源的MSC相似的免疫调节特性。由于人胚胎干细胞的衍生物已经进入I期临床试验的背景下的临床竞技场，因此胚胎干细胞衍生的间充质干细胞的免疫调节特性可能被证明对于其未来的潜在临床应用具有高度价值。
Mesenchymal stromal cells (MSCs) originally isolated from bone marrow have multipotent differentiation potential, and favorable immunomodulatory and anti-inflammatory properties that make them very attractive for regenerative cellular therapy. Cells with similar phenotypic characteristics have now been derived from almost all fetal, neonatal and adult tissues; furthermore, more recently similar cells have also been generated from human embryonic stem cells (ESCs). Generation of MSCs from human ESCs provides an opportunity to study the developmental biology of human mesenchymal lineage generation in vitro. Generation of bone and cartilage from human ESC-derived MSCs and their functional characterization, both in vitro and in vivo, is also an active area of investigation as ESCs could provide an unlimited source of MSCs for potential repair of bone and cartilage defects. MSCs from adult sources are being investigated in numerous phase I-III clinical trials for a wide variety of indications, mainly based on their immunomodulatory properties. Our group and others have shown MSCs derived from human ESCs possess immunomodulatory properties similar to bone marrow-derived MSCs. Immunomodulatory properties of ESC-derived MSCs could prove to be highly valuable for their potential clinical applications in the future as derivatives of human ESCs have already entered clinical arena in the context of phase-I clinical trials.
登录
查看更多内容
影响因子：
15.8
作者：
Barberi T;Willis LM;Socci ND;Studer L
通讯作者：
Studer L
影响因子：
11.2
作者：
Bang, OY;Lee, JS;Lee, G
通讯作者：
Lee, G
影响因子：
6.2
作者：
Dominici, Massimo;Paolucci, Paolo;Horwitz, Edwin M.
通讯作者：
Horwitz, Edwin M.
影响因子：
7.7
作者：
Abdi R;Fiorina P;Adra CN;Atkinson M;Sayegh MH
通讯作者：
Sayegh MH
影响因子：
5.2
作者：
Dihne, Marcel;Bernreuther, Christian;Schachner, Melitta
通讯作者：
Schachner, Melitta